|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02666 UNI MEDICAL
Nominal 
4.680 +0.060 (+1.299%) | 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Turnover | 6,542,690 | -2.914% | 13,650,203 | 12,073,172 | 9,914,273 | 8,521,238 |
| Cost of Sales | (4,278,866) | -4.193% | (9,078,344) | (7,578,878) | (5,714,834) | (4,967,263) |
| Gross Profit | 2,263,824 | -0.402% | 4,571,859 | 4,494,294 | 4,199,439 | 3,553,975 |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (109,083) | 14.904% | (192,099) | (307,139) | (318,235) | (247,446) | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | (613) | 559.140% | (1,624) | (1,154) | (942) | -- | |
| Share of Results of Asso. & JCEs | 13,636 | 161.527% | 6,380 | 13,462 | 13,865 | 11,347 | |
| Profit / (Loss) before Taxation | 1,618,674 | 3.464% | 2,866,213 | 2,703,274 | 2,691,808 | 2,365,014 | |
| Taxation | (366,501) | -0.871% | (667,141) | (617,326) | (661,339) | (551,104) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (79,209) | 44.276% | (88,735) | (126,128) | (82,739) | (66,773) | |
| Others | (35,729) | -16.507% | (89,419) | (71,403) | (112,497) | (99,600) | |
| Profit / (Loss) Attributable to Shareholders | 1,137,235 | 3.662% | 2,020,918 | 1,888,417 | 1,835,233 | 1,647,537 | |
| 2024/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | |
| Net Finance Costs / (Income) | (6,014) | -82.460% | (45,075) | (38,517) | (27,564) | (12,996) |
| Depreciation & Amortisation | 262,063 | 7.041% | 508,665 | 442,049 | 319,464 | 269,193 |
| Directors' Emoluments | -- | -- | 13,785 | 14,631 | 12,354 | 12,204 |
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2024/06 - Interim | %Chg (Compare to Interim) | 2023/12 | 2022/12 | 2021/12 | 2020/12 | |
| EPS (cts) | 60.000 | 3.448% | 107.000 | 100.000 | 99.000 | 96.000 |
| DPS (cts) | 0.000 | -- | 31.740 | 29.788 | 29.264 | 26.154 |
| Dividend Payout Ratio (%) | -- | -- | 29.664% | 29.788% | 29.559% | 27.243% |
| Cash flow per share ($) | -- | -- | 2.640 | 1.074 | (0.753) | (0.566) |
| NBV per share ($) | 8.940 | -- | 8.248 | 7.351 | 6.888 | 6.275 |
| Remarks: | Real time quote last updated: 29/11/2024 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 1,137,235 |
| %Change | 3.662% |
| EPS / (LPS) | RMB 0.600 |
| NBV Per Share (¥) | RMB 8.940 |